Dermata Therapeutics
Developing Bioneedle-based skincare for consumer and professional channels.
Something off on this page? Send us feedback.
Profile
Develops a direct-to-consumer and professional skincare line around Bioneedle, a freshwater-sponge-derived powder. Intended revenue begins with Tome Foundational Treatment, leaving execution dependent on an uncommercialized launch, outsourced operations, and an exclusive Russian raw-material supplier.
Builds the Tome skincare line around Bioneedle, a purified powder derived from freshwater Spongilla. Its first planned product, Tome Foundational Treatment, is a once-weekly cosmetic skin-renewal treatment; a Clearing Treatment that pairs Bioneedle with a daily salicylic-acid wipe remains in development.
Intends to sell through direct-to-consumer e-commerce and to aestheticians and dermatologists, with U.S.-centered operations and international supply and patent activity. The company applies experience from prior prescription-drug development to consumer and professional skincare, while outsourcing supply, manufacturing, distribution, delivery, and IT.
Commercial execution depends on acceptance of an initial product that had not yet generated sales, an exclusive Russian source for Spongilla raw material, and compliance with cosmetic and OTC claims, manufacturing, and labeling requirements.
Company facts
Key statistics
Year to date −38.5% · Average volume (30d) 1.4M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.55 | −$0.74 | −34.5% | — | — | — | +27.78% |
| May 13, 2026Q1 FY26 | −$0.53 | −$0.48 | +9.4% | — | — | — | +3.36% |
| Mar 26, 2026Q4 FY25 | −$1.54 | −$1.52 | +1.3% | — | — | — | −13.87% |
| Nov 14, 2025Q3 FY25 | −$1.59 | −$1.65 | −3.8% | — | — | — | −7.49% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$2.3M | −$1.8M | −$1.8M | −$1.9M | −$1.9M | −$3.0M | |
| Net income | −$2.3M | −$1.7M | −$1.7M | −$1.9M | −$1.8M | −$3.0M | |
| Diluted EPS | −$4.47 | −$1.66 | −$1.65 | −$1.52 | −$0.48 | −$0.74 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $4.4M · Total debt $0 · Total assets $5.3M · Shareholders' equity $3.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 681.6K · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 672.1K | 9.99% | 13G | Aug 14, 2025 |
| Kyri K. Van Hoose | 384.4K | 9.00% | 13D | Jun 1, 2026 |
| Gerald T. Proehl · director, 10 percent owner, officer: PRESIDENT, CHAIRMAN, CEO | 292.6K | 42.94% | Form 4 | Aug 18, 2026 |
| Kyri K. van Hoose · officer: SVP, CFO | 232.5K | 34.11% | Form 4 | Aug 18, 2026 |
| Mitchell P. Kopin | 147.1K | 5.50% | 13G | Jan 2, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 16, 2026 | Kathleen D. Scott | director | −11 | $1.19 |
| Feb 17, 2026 | Munera Maria E. Bedoya-Toro | officer: SVP, Regulatory Affairs | +1,000 | $1.27 |
Peers
- Kenvue
Mass-retail Neutrogena acne and renewal lines capture the same spend.
- Hims & Hers Health
Apostrophe teledermatology diverts DTC acne-seeking consumers.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dermata Therapeutics | $1.34 | 0.00% | $913.3K | — | — | — | — |
| Kenvue | $19.17 | +0.03% | $36.81B | 22.0 | 16.0 | 2.4 | +3.0% |
| Hims & Hers Health | $28.86 | +0.10% | $6.43B | — | 110.6 | 2.5 | +38.3% |
| Median | 22.0 | 63.3 | 2.4 | +20.6% |